Cargando…

International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol

BACKGROUND: Clinically useful treatment moderators of Major Depressive Disorder (MDD) have not yet been identified, though some baseline predictors of treatment outcome have been proposed. The aim of iSPOT-D is to identify pretreatment measures that predict or moderate MDD treatment response or remi...

Descripción completa

Detalles Bibliográficos
Autores principales: Williams, Leanne M, Rush, A John, Koslow, Stephen H, Wisniewski, Stephen R, Cooper, Nicholas J, Nemeroff, Charles B, Schatzberg, Alan F, Gordon, Evian
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3036635/
https://www.ncbi.nlm.nih.gov/pubmed/21208417
http://dx.doi.org/10.1186/1745-6215-12-4
_version_ 1782197879522197504
author Williams, Leanne M
Rush, A John
Koslow, Stephen H
Wisniewski, Stephen R
Cooper, Nicholas J
Nemeroff, Charles B
Schatzberg, Alan F
Gordon, Evian
author_facet Williams, Leanne M
Rush, A John
Koslow, Stephen H
Wisniewski, Stephen R
Cooper, Nicholas J
Nemeroff, Charles B
Schatzberg, Alan F
Gordon, Evian
author_sort Williams, Leanne M
collection PubMed
description BACKGROUND: Clinically useful treatment moderators of Major Depressive Disorder (MDD) have not yet been identified, though some baseline predictors of treatment outcome have been proposed. The aim of iSPOT-D is to identify pretreatment measures that predict or moderate MDD treatment response or remission to escitalopram, sertraline or venlafaxine; and develop a model that incorporates multiple predictors and moderators. METHODS/DESIGN: The International Study to Predict Optimized Treatment - in Depression (iSPOT-D) is a multi-centre, international, randomized, prospective, open-label trial. It is enrolling 2016 MDD outpatients (ages 18-65) from primary or specialty care practices (672 per treatment arm; 672 age-, sex- and education-matched healthy controls). Study-eligible patients are antidepressant medication (ADM) naïve or willing to undergo a one-week wash-out of any non-protocol ADM, and cannot have had an inadequate response to protocol ADM. Baseline assessments include symptoms; distress; daily function; cognitive performance; electroencephalogram and event-related potentials; heart rate and genetic measures. A subset of these baseline assessments are repeated after eight weeks of treatment. Outcomes include the 17-item Hamilton Rating Scale for Depression (primary) and self-reported depressive symptoms, social functioning, quality of life, emotional regulation, and side-effect burden (secondary). Participants may then enter a naturalistic telephone follow-up at weeks 12, 16, 24 and 52. The first half of the sample will be used to identify potential predictors and moderators, and the second half to replicate and confirm. DISCUSSION: First enrolment was in December 2008, and is ongoing. iSPOT-D evaluates clinical and biological predictors of treatment response in the largest known sample of MDD collected worldwide. TRIAL REGISTRATION: International Study to Predict Optimised Treatment - in Depression (iSPOT-D) ClinicalTrials.gov Identifier: NCT00693849 URL: http://clinicaltrials.gov/ct2/show/NCT00693849?term=International+Study+to+Predict+Optimized+Treatment+for+Depression&rank=1
format Text
id pubmed-3036635
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-30366352011-02-10 International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol Williams, Leanne M Rush, A John Koslow, Stephen H Wisniewski, Stephen R Cooper, Nicholas J Nemeroff, Charles B Schatzberg, Alan F Gordon, Evian Trials Study Protocol BACKGROUND: Clinically useful treatment moderators of Major Depressive Disorder (MDD) have not yet been identified, though some baseline predictors of treatment outcome have been proposed. The aim of iSPOT-D is to identify pretreatment measures that predict or moderate MDD treatment response or remission to escitalopram, sertraline or venlafaxine; and develop a model that incorporates multiple predictors and moderators. METHODS/DESIGN: The International Study to Predict Optimized Treatment - in Depression (iSPOT-D) is a multi-centre, international, randomized, prospective, open-label trial. It is enrolling 2016 MDD outpatients (ages 18-65) from primary or specialty care practices (672 per treatment arm; 672 age-, sex- and education-matched healthy controls). Study-eligible patients are antidepressant medication (ADM) naïve or willing to undergo a one-week wash-out of any non-protocol ADM, and cannot have had an inadequate response to protocol ADM. Baseline assessments include symptoms; distress; daily function; cognitive performance; electroencephalogram and event-related potentials; heart rate and genetic measures. A subset of these baseline assessments are repeated after eight weeks of treatment. Outcomes include the 17-item Hamilton Rating Scale for Depression (primary) and self-reported depressive symptoms, social functioning, quality of life, emotional regulation, and side-effect burden (secondary). Participants may then enter a naturalistic telephone follow-up at weeks 12, 16, 24 and 52. The first half of the sample will be used to identify potential predictors and moderators, and the second half to replicate and confirm. DISCUSSION: First enrolment was in December 2008, and is ongoing. iSPOT-D evaluates clinical and biological predictors of treatment response in the largest known sample of MDD collected worldwide. TRIAL REGISTRATION: International Study to Predict Optimised Treatment - in Depression (iSPOT-D) ClinicalTrials.gov Identifier: NCT00693849 URL: http://clinicaltrials.gov/ct2/show/NCT00693849?term=International+Study+to+Predict+Optimized+Treatment+for+Depression&rank=1 BioMed Central 2011-01-05 /pmc/articles/PMC3036635/ /pubmed/21208417 http://dx.doi.org/10.1186/1745-6215-12-4 Text en Copyright ©2011 Williams et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<url>http://creativecommons.org/licenses/by/2.0</url>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Study Protocol
Williams, Leanne M
Rush, A John
Koslow, Stephen H
Wisniewski, Stephen R
Cooper, Nicholas J
Nemeroff, Charles B
Schatzberg, Alan F
Gordon, Evian
International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol
title International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol
title_full International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol
title_fullStr International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol
title_full_unstemmed International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol
title_short International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol
title_sort international study to predict optimized treatment for depression (ispot-d), a randomized clinical trial: rationale and protocol
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3036635/
https://www.ncbi.nlm.nih.gov/pubmed/21208417
http://dx.doi.org/10.1186/1745-6215-12-4
work_keys_str_mv AT williamsleannem internationalstudytopredictoptimizedtreatmentfordepressionispotdarandomizedclinicaltrialrationaleandprotocol
AT rushajohn internationalstudytopredictoptimizedtreatmentfordepressionispotdarandomizedclinicaltrialrationaleandprotocol
AT koslowstephenh internationalstudytopredictoptimizedtreatmentfordepressionispotdarandomizedclinicaltrialrationaleandprotocol
AT wisniewskistephenr internationalstudytopredictoptimizedtreatmentfordepressionispotdarandomizedclinicaltrialrationaleandprotocol
AT coopernicholasj internationalstudytopredictoptimizedtreatmentfordepressionispotdarandomizedclinicaltrialrationaleandprotocol
AT nemeroffcharlesb internationalstudytopredictoptimizedtreatmentfordepressionispotdarandomizedclinicaltrialrationaleandprotocol
AT schatzbergalanf internationalstudytopredictoptimizedtreatmentfordepressionispotdarandomizedclinicaltrialrationaleandprotocol
AT gordonevian internationalstudytopredictoptimizedtreatmentfordepressionispotdarandomizedclinicaltrialrationaleandprotocol